Celcuity (CELC) – Company Press Releases
-
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
-
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
-
Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024
-
Celcuity to Participate in Cowen’s 44th Annual Health Care Conference
-
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer
-
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
-
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium
-
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium
-
Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference
-
Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
-
Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call
-
Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences
-
Celcuity Inc. Announces $50 Million Private Placement
-
Celcuity to Host Virtual Science Day for Investors
-
Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial
-
Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer
-
Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
-
Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call
-
Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023
-
Celcuity Set to Join Russell 2000 and 3000 Indexes
-
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
-
Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates
-
Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress
-
Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call
-
Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress
-
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
-
Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference
-
Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call
-
Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
-
Celcuity to Participate in Cowen's 43rd Annual Health Care Conference
-
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium
-
Celcuity Closes $100 Million Private Placement
-
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium
-
Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer
-
Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium
-
Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference
-
Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call
-
Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors
-
Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call
-
Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference
-
Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer
-
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
-
Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates
-
Celcuity Inc. Announces $100 Million Private Placement
-
Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call
-
Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences
Back to CELC Stock Lookup
